The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Eli Lilly clears a major legal hurdle in its Centessa deal after UK High Court approval
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 22, 4:22 PM EDT

Eli Lilly clears a major legal hurdle in its Centessa deal after UK High Court approval

The UK’s High Court of Justice has approved Eli Lilly’s acquisition of Centessa Pharmaceuticals plc, advancing a transaction aimed at expanding Lilly’s pipeline beyond current sleep disorder assets.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly has received approval from the High Court of Justice of England and Wales for its acquisition of Centessa Pharmaceuticals plc, according to a business report published June 22, 2026.

Centessa, listed on the Nasdaq under the ticker CNTA, is described in the report as a clinical-stage company developing a new class of medicines focused on the treatment of excessive daytime sleepiness. The company’s work is positioned in the report as part of an emerging approach to sleep-related disorders, areas where Lilly has broader pharmaceutical interests but where Centessa’s early-stage programs are meant to add incremental scientific and clinical depth.

For Lilly, a court sanction is a critical procedural step in completing certain types of UK restructurings and deal mechanisms. The High Court approval indicates that the transaction has passed a key legal review in England and Wales, reducing one of the remaining uncertainties that can slow merger timelines.

The approval comes as drugmakers increasingly use acquisitions to add late-breaking clinical candidates rather than relying solely on internal discovery. Clinical-stage companies like Centessa can offer platforms or therapeutic candidates that, if they progress, may broaden a buyer’s ability to compete in therapeutic categories that have growing demand or clear clinical endpoints.

Market participants typically watch UK court approvals closely because they can be a gating item for closing, particularly in cross-border transactions that require shareholder and regulatory steps across jurisdictions. While this approval addresses a major legal checkpoint, it does not by itself guarantee that all remaining conditions for closing have been satisfied.

Centessa’s focus on excessive daytime sleepiness is also notable because it targets a symptom-driven clinical area with meaningful patient impact. Drug developers in sleep-related indications often face intense scrutiny around efficacy, tolerability, and trial design, since patient heterogeneity can affect outcomes.

At this point, the court approval is the clearest reported milestone. The broader timeline for deal completion, including any remaining approvals or documentation steps, was not detailed in the published report referenced in this article.

What to watch next is whether the parties can move from court-sanctioned approval to final completion steps, and whether additional communications clarify the next expected milestone dates. Companies and investors will also look for any follow-on disclosures tied to integration planning and how Centessa’s development programs will be slotted into Lilly’s broader pipeline strategy.

Why It Matters

  • A UK High Court approval is a significant gating item in certain deal structures, which can shorten or de-risk the path to transaction completion.
  • Acquiring a clinical-stage portfolio can help a large pharma company accelerate pipeline breadth in therapeutic areas where it wants more candidates.
  • Court-approved transactions can reduce one category of execution risk, which often improves deal visibility for investors even if other conditions remain.

Sources

Key Facts

  • Eli Lilly said it obtained approval from the High Court of Justice of England and Wales for its acquisition of Centessa Pharmaceuticals plc.
  • The reported transaction involves Centessa Pharmaceuticals plc, which trades on the Nasdaq under the ticker CNTA.
  • Centessa is described as a clinical-stage company developing a new class of medicines focused on excessive daytime sleepiness.
  • The June 22, 2026 court approval is presented as a major procedural step toward completing the deal.
  • No deal pricing or detailed closing timetable was provided in the available source context used for this report.

Healthcare Related

Eli Lilly clears a major legal hurdle in its Centessa deal after UK High Court approval | The Apex Times